Canada Post Corp Registered Pension Plan Has $11.64 Million Position in Gilead Sciences, Inc. $GILD

Canada Post Corp Registered Pension Plan grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 110.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 103,344 shares of the biopharmaceutical company’s stock after purchasing an additional 54,231 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Gilead Sciences were worth $11,639,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Corundum Trust Company INC bought a new stake in Gilead Sciences during the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth approximately $27,000. Howard Hughes Medical Institute bought a new position in Gilead Sciences in the second quarter valued at approximately $30,000. Finally, Putney Financial Group LLC boosted its holdings in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 373,037 shares of company stock worth $50,731,512. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. TD Cowen raised their price objective on shares of Gilead Sciences from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Needham & Company LLC upped their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Sanford C. Bernstein set a $135.00 target price on Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. Finally, Truist Financial boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $136.73.

Gilead Sciences Trading Up 2.1%

Shares of Gilead Sciences stock opened at $152.50 on Friday. The stock has a market cap of $189.20 billion, a P/E ratio of 23.64, a P/E/G ratio of 0.79 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $153.13. The business’s 50 day moving average is $127.38 and its 200-day moving average is $120.91.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.